The FDA has granted 510(k) clearance for MODI, a mobile app from Israeli company DreaMed Diabetes that uses continuous glucose monitoring data to automatically optimize insulin dosing recommendations for adults with type 2 diabetes. This is the first insulin titration algorithm cleared for this patient population.
Blue Cross Blue Shield Association released a study claiming AI-backed billing tools used by healthcare providers have generated nearly $1 billion in additional costs over two years by enabling more severe patient care coding. The companies making these AI tools dispute the findings, arguing the problem lies with the healthcare billing system itself rather than the technology.
Intermountain Health is implementing AI tools for clinical documentation with applications extending beyond traditional in-appointment note-taking and diagnostic assistance, focusing on administrative and workflow improvements outside the exam room.
A geriatrician is raising concerns about the need for careful evaluation of artificial intelligence technologies being developed for use with older adult populations, highlighting potential risks and the importance of rigorous oversight in this emerging area of health technology.
Bodies donated to science are being utilized as a source of high-precision anatomic data to support the development and validation of medical AI systems, three-dimensional models, and related applications, raising questions about innovation and ethical considerations.
Two new AI developments improve breast cancer risk prediction and detection: a deep learning model using 3D mammography (digital breast tomosynthesis) shows superior 5-year risk prediction compared to traditional 2D mammography-based AI, while AIIMS Delhi has developed an AI tool to serve as a second reader of mammograms, now licensed to BPL Technologies.
Health Secretary Robert F. Kennedy Jr. announced a new federal initiative to improve autism diagnoses using AI and other technology to map how the condition develops and enable earlier intervention, arguing the current diagnostic model is outdated and too time-intensive.
A large international real-world study found that a multimodal explainable AI decision support tool outperformed established biomarkers for predicting immunotherapy outcomes in non-small cell lung cancer and improved physician decision-making.
The Advanced Research Projects Agency for Health (ARPA-H) announced a $62 million investment to fund teams competing to build an FDA-authorized artificial intelligence tool capable of making complex clinical decisions for heart care and treating heart failure.
Rentosertib, an experimental lung disease drug developed using artificial intelligence, demonstrated the ability to reverse biological signs of aging in a study, according to its developer, suggesting broader potential applications beyond its original target condition.
The FDA has accepted AI products from Cadence and Limbic, along with two other devices, into its TEMPO pilot program, which will allow these digital health companies to release their products to patients before receiving full marketing authorization.
As AI technology becomes ubiquitous, consumer wariness is growing even as the technology demonstrates concrete benefits like accelerating rare disease diagnoses. Anthropic CEO Dario Amodei argues the industry needs major scientific breakthroughs like curing cancer to win public acceptance.
Flinders University researchers evaluated two advanced reasoning large language models—o3-mini and DeepSeek-R1—and discovered they continue to reproduce racial and gender stereotypes when describing fictional patients with common medical conditions, despite being newer generation AI systems.
Scientists at Stanford University and the Arc Institute created the first functional bacteriophage viruses designed entirely by AI genome language models, marking a milestone in synthetic biology while raising urgent biosecurity and governance concerns.
The University of Oxford spinout Caristo has received FDA authorization for an AI-powered tool designed to assess heart attack risk in patients without obstructive coronary artery disease. The company plans to launch the cardiovascular risk predictor soon.
Researchers have developed a novel artificial intelligence model that analyzes data from routine polysomnography sleep studies to identify patients' long-term health risks, including cognitive decline. The study was published in Nature Communications.
A University of Colorado Anschutz-led randomized clinical trial found that an automated oxygen delivery system kept hospitalized patients in their target oxygen range 85% of the time, compared to 63% with manual adjustments by healthcare staff.
Insilico Medicine CEO Alex Zhavoronkov told Reuters that the company typically reaches a developmental drug candidate in 13 months, with a record of nine months, by combining AI with its research operations in China. Reuters reported that China has become a major hub for next-generation medicine development, aided by lower research costs and streamlined regulation.
Intuitive Surgical presented a five-layer framework for AI-enabled surgical care and announced plans for a live telesurgery demonstration connecting its facilities in Sunnyvale, California, and Atlanta, Georgia. The planned demonstration was to use a da Vinci 5 system on an advanced tissue model and did not involve surgery on a patient.
Utah has become the first U.S. state to allow an AI chatbot to renew prescriptions without a doctor's visit through a program run by Doctronic that launched in January 2026, triggering concerns from medical professionals about whether artificial intelligence is ready to handle traditionally doctor-only responsibilities.
A new AI tool successfully identified early signs of pancreatic cancer in CT scans that human doctors would miss, potentially enabling detection up to three years before conventional diagnosis in initial testing.
Singapore Health Minister Ong Ye Kung and healthcare industry experts warn that public distrust could derail AI implementation in healthcare, calling for balanced approaches to patient data and responsible deployment frameworks. Singapore is piloting AI clinical decision support tools through its SIMFONI initiative for chronic disease management.
Singapore Health Minister Ong Ye Kung and healthcare industry experts highlight that public distrust poses a fundamental barrier to AI adoption in healthcare, as the sector continues to lag behind other industries in implementation despite initiatives like Singapore's SIMFONI AI model for chronic disease management.
The Advanced Research Projects Agency for Health (ARPA-H) announced a new program called IGoR designed to deliver rigorous, gold-standard research faster by using AI to guide experiments in complex, under-explored areas of science.
A Harvard study found that AI systems surpassed physicians in diagnostic accuracy for emergency room triage cases, with researchers noting they've reached "the ceiling" of AI diagnostic capabilities. The findings have generated significant attention though experts caution against overhyping the results.
Researchers published in Science results showing an OpenAI artificial intelligence model outperformed physicians on diagnostic and clinical reasoning tasks, including real emergency department data, in one of the largest AI-physician comparison studies to date.
Mayo Clinic's AI-assisted test model (REDMOD) can detect pancreatic ductal adenocarcinoma at stage 0, identifying subtle tissue changes up to three years before conventional diagnosis, validated in a landmark study.
Utah's medical board demanded immediate suspension of a state pilot program using artificial intelligence bots to renew prescriptions, citing concerns about patient safety and appropriate medical oversight.
Northwestern Medicine study found AI models from Meta, Google, and DeepMind generate more complete summaries of complex cancer pathology reports than physicians, potentially improving clinical communication and patient understanding.
China has granted commercial-use approval for an implantable brain-computer interface device, becoming the first country to approve an invasive BCI for use outside clinical trials after a two-decade development race with the United States.
Pharmaceutical giant Eli Lilly has agreed to a global licensing and research collaboration with AI drug developer Insilico Medicine, providing $115 million upfront with potential total value reaching $2.75 billion. The deal expands an existing partnership focused on using artificial intelligence for drug discovery.
Researchers have developed artificial intelligence tools to support clinical decision-making in hematologic malignancies, including HemaGuide from German Cancer Research Center for treatment recommendations and AI applications in palliative oncology for symptom management and prognostication.
